TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SpaceOAR System Pivotal Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects greater than 18 years old~* Subjects must have pathologically confirmed invasive adenocarcinoma of the prostate and must be planning to undergo IMRT~* Subjects must have clinical stage T1 or T2 as determined from a biopsy taken within 6 months of the baseline/screening visit with Gleason Score less than or equal to 7~* Subjects Screening/Baseline laboratory testing must meet the following laboratory value criteria: PSA less than or equal to 20 ng/mL,hematocrit greater than 30%,serum creatinine less than 2.0 mg/dl, serum AST and ALT less than 2.5 times upper limit of institution normal, and serum bilirubin less than 2.0 mg/dl~* Subject or authorized representative, has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site~Exclusion Criteria:~* Prostate greater than 80cc documented within 3 months preceding the Screening/Baseline visit~* Subjects with extracapsular extension of the prostate cancer, with greater than 50% of the number of biopsy cores positive for cancer, metastatic disease, other ongoing cancers which will be treated during the study, or subjects for whom pelvic lymph node radiotherapy is planned~* Subjects with any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject has been disease free for a minimum of 5 years.~* Subjects who are indicated for androgen deprivation therapy or who have been treated with androgen therapy within the prior 3 months.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SpaceOAR (Type: EXPERIMENTAL): Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
- Control (Type: NO_INTERVENTION): Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treximet ™ Pharmacy Budget Impact Model Database Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least one prescription claim for either Treximet ™ or orally administered triptan~* at least 18 years of age at index Rx date~* at least one prescription claim for any medication in the pre- and post-index period (proxy for continuous enrollment)~Exclusion Criteria:~* Subjects receiving nasal sumatriptan at any time~* Subjects over 65 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- adult migraineurs with/without aura (Type: None): Adult migraine patients \>18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age 18 to 65 years,~2. DSM-IV episode of Major Depression non-psychotic with atypical features.~3. ≥19 score on the 29-item HAM-D,~4. ability to give informed consent, if patients are of child-bearing potential~5. A minimum 2-week washout from existing psychotropics (5 weeks for fluoxetine).~Exclusion Criteria:~1. bipolar depression,~2. Any Axis I psychotic disorder~3. currently suicidal or suicide risk,~4. history of substance abuse in the previous 12 months,~5. history of hypersensitivity to escitalopram, or citalopram~6. serious or unstable medical disorders,~7. starting or terminating psychotherapy during the previous 12 weeks,~8. ECT treatment in the previous 3 months,~9. pregnancy or planning pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Lexapro

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RhD+ Blood Transfusion to Asian-type DEL Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria for eligible participants were as follows: (1) Asian-type DEL blood group; (2) male patients, or female patients ≥ 49 years of age, or female with severe illness and no plan for further pregnancy; (3) needing blood transfusion in line with guidelines for internal medicine or surgery; and (4) signed voluntary informed consent for blood transfusion treatment before the trial.~The exclusion criteria were: (1) adverse reaction in a previous transfusion; (2) allergies to blood products or immunodeficiency diseases; (3) needing massive blood transfusion for acute blood loss; (4) positive pregnancy test results; (5) conscious dysfunction or severe mental illness; and (6) unsuitability for the study, as estimated by the principal investigators.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asian-type DEL recipients (Type: EXPERIMENTAL): First, to identify Asian-type DEL patients by phenotyping and genotyping methods in the Chinese recipients having a serologically apparent RhD-negative phenotype.~Then, blood transfusion of RhD+ blood rather than rare RhD-negative blood to the Asian-type DEL recipients which met the inclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing an mHealth Intervention to Change Food Purchasing Behaviors for Cancer Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~* 18 years or older~* Fluent in English~* Low adherence to cancer prevention dietary guidelines, operationalized as a score of ≤ 2 out of 4 using the National Cancer Institute method for assessing adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations. This three-level scoring system (meeting/partially meeting/not meeting each recommendation) includes 4 items specific to diet. Participants must score equal or less than 2, meaning that they are fully meeting recommendations for no more than 2 of the 4 dietary recommendations.~* Performs the majority of the household's food shopping, and do so at stores that can passively stream item-level data from a store loyalty card to the Information Machine API (e.g., Walmart, Target, ShopRite, Wegman's, etc.)~* Has a smartphone with iOS or Android operating system that is compatible with the program app~* Lives in a household with at least one other adult who consents to being randomized to possibly receive messages on his/her own cell phone through the program app~Exclusion criteria~* Medical condition or psychiatric condition (e.g., active substance abuse, eating disorder) that may limit appropriateness of or ability to comply with program dietary recommendations~* Planning to enroll in another lifestyle modification program in the next 6 months~* Bariatric surgery history~* Currently pregnant or breastfeeding or planning to become pregnant in the next 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LOCATION TRIGGERED MESSAGING (Type: EXPERIMENTAL): Weekly message is triggered when arriving at grocery store.
- COACH MONITORING (Type: EXPERIMENTAL): Coaches view grocery purchases via web portal, send weekly messages about purchases they observe, and conduct three brief phone calls to discuss purchases.
- BENEFITS OF CHANGE (Type: EXPERIMENTAL): Attend an extra workshop session and three phone calls to identify and reflect on benefits of dietary change. Content added to standard weekly messages about benefits of change.
- HOUSEHOLD SUPPORT (Type: EXPERIMENTAL): An adult household member attends one workshop session and three phone calls with the index participant. This household member receives weekly text messages for 20 weeks about program goals and ways to support the index participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine on Parturient Undergoing Elective Cesarean Section.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA class I or II~2. BMI≦35kg/m2~3. Greater than 37 weeks gestation~4. Expressed a desire to breastfeed for a least 3 months postpartum~5. Elective cesarean section~Exclusion Criteria:~1. Intraspinal anesthesia contraindication~2. Twin or fetal Intrauterine distress~3. Preoperative history of application of analgesia or sedative drug~4. Severe cardiac and pulmonary dysfunction~5. History of neurological and psychiatric diseases

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine group (Type: EXPERIMENTAL): After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
- control group (Type: PLACEBO_COMPARATOR): Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma based upon standard criteria~* Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of \> 1 g/dl and/or urine monoclonal immunoglobulin spike of \> 200mg/24 hours.~* Karnofsky performance status of \> 60~* Hemoglobin \> 8.0 g/dL~* AST (SGOT) \< 3 x ULN~* ALT \< 3 x ULN~* Total bilirubin \< 2 x ULN~* Is infertile or is practicing an adequate form of contraception~* 18 years of age or older~Exclusion Criteria:~* Prior treatment with systemic chemotherapy~* Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes~* Plasma cell leukemia~* Calculated or measured creatinine clearance \< 30 mL/minute within 14 days of enrollment~* Grade 2 or greater peripheral neuropathy~* Hypersensitivity to bortezomib, boron or mannitol~* Severe hypercalcemia~* HIV positive~* Known active hepatitis B or C~* New York Hospital Association Class III or IV heart failure~* Second malignancy requiring concurrent treatment~* Other serious medical or psychiatric illness~* Pregnant women~* Dialysis dependent patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib (Type: EXPERIMENTAL): Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe chronic plaque psoriasis~* Active psoriasis, despite topical therapies~Exclusion Criteria:~* Other active skin diseases or skin infections~* Prior exposure to any anti-TNF therapy~* Subject has other active skin diseases~* Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other systemic PS therapies)~* Poorly controlled medical conditions~* History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease.~* History of cancer or lymphoproliferative disease~* History of active TB or listeriosis, or persistent chronic or active infections~* Known to have immune deficiency or is immunocompromised~* Clinically significant abnormal laboratory test results~* Erythrodermic psoriasis or generalized pustular psoriasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* 40 - 80 years of age~* Clinical history of COPD with airflow limitation that is not fully reversible~* Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods~* Current/former smokers with at least a 10 pack-year history of cigarette smoking~* A measured post- bronchodilator FEV1/FVC ratio of \< or = 0.70~* A measured post- bronchodilator FEV1 \> or = 750ml or 30% predicted and \< or = 80% of predicted normal values~* Able to change COPD treatment as required by protocol~Exclusion Criteria:~* Women who are pregnant or lactating~* Primary diagnosis of asthma~* Alpha-1 antitrypsin deficiency as the cause of COPD~* Active pulmonary diseases~* Prior lung volume reduction surgery~* Abnormal chest X-ray (or CT scan) not due to the presence of COPD~* Hospitalized due to poorly controlled COPD within 3 months of Screening~* Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)~* Cancer that has not been in complete remission for at least 5 years~* Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives~Other inclusion/exclusion criteria as defined in the protocol

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- PT001 MDI (Dose 1) (Type: EXPERIMENTAL): None
- PT001 MDI (Dose 2) (Type: EXPERIMENTAL): None
- PT001 MDI (Dose 3) (Type: EXPERIMENTAL): None
- PT001 MDI (Dose 4) (Type: EXPERIMENTAL): None
- PT001 MDI (Dose 5) (Type: EXPERIMENTAL): None
- PT001 MDI (Dose 6) (Type: EXPERIMENTAL): None
- PT001 Placebo MDI (Type: PLACEBO_COMPARATOR): None
- Spiriva® Handihaler® (Tiotropium Bromide) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kilimanjaro IPTi Drug Options Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All infants attending EPI clinics at the 12 study health facilities for first vaccinations. Infants who live within the catchment area of the study health facility and are less than 3 months of age at the time of DPT and Polio 1 vaccination will be eligible for inclusion in the study.~Exclusion Criteria:~* Infants having any of the following conditions will be excluded: (1) history of allergy to study drugs; (2) history of convulsions; (3) clinical features of severe malnutrition or chronic illness including infants with signs of AIDS \[HIV prevalence in women of reproductive age in the study area was 11.5% in 1999\]39 (4) plans to leave the study area before 12 months of age.(5) weighs \<4.5 kgs (6) caretaker declines to give consent.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): IPTi placebo
- Sulphadoxine-pyrimethamine (Type: EXPERIMENTAL): IPTi SP
- Mefloquine (Type: EXPERIMENTAL): None
- Chlorproguanil dapsone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Diagnosis of CLL/SLL which is made according to the updated criteria of the NCI Working Group~* Cohort 1:Treatment naive CLL/SLL patients~* Cohort 2: Subjects must be receiving treatment ibrutinib for at least 6 months prior to administration of the first vaccine dose~* Cohort 3: Subjects must be receiving acalabrutinib for at least 6 months prior to administration of the first vaccine dose~* No active, symptomatic VZV or herpes zoster infection within 12 months prior to vaccination~* No exposure to the live VZV vaccine (ZOSTAVAX) within 12 months prior to vaccination~* No prior exposure to the SHINGRIX vaccine~* Age greater than or equal to 18 years.~* ECOG performance status of 0-2~* Able to comprehend the investigational nature of the protocol and provide informed consent~EXCLUSION CRITERIA:~* Female patients who are currently in pregnancy~* Any uncontrolled active systemic infection~* Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk~* Severe allergic reaction to any component of SHINGRIX.~* Received intravenous immunoglobulin (IVIG) within 3 months prior to vaccination.~* Concomitant use of immunosuppressive agents (e.g. steroids, radio~therapy, chemotherapy)~* Hereditary or acquired immunodeficiency syndrome unrelated to chronic lymphocytic leukemia~* Non-English speaking individuals will be excluded from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Chronic Lymphocytic Leukemia Patients That Are Treatment Naive (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
- Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
- Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must complete TEN-02-301 (PHREEDOM)~Exclusion Criteria:~1. Schedlued for kidney transplant~2. Life expectancy \<12 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenapanor w/Sevelamer (Type: EXPERIMENTAL): Tenapanor will be administered QD or BID and sevelamer can be added to achieve desired serum phosphorus level
- Sevelamer w/Tenapanor (Type: EXPERIMENTAL): Sevelamer will be administered QD, BID or TID and tenapanor will be added to achieve desired serum phosphorus level and sevelamer dose will be decreased as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete